INTRODUCTION 24
Hepatocellular carcinoma (HCC) is a primary liver tumor that typically arises in a 25 background of chronic liver disease and cirrhosis (1). One of the key players in the 26 progression of cirrhosis to HCC is the hepatic stellate cell, which activates during liver 1 damage and differentiates towards a contractile myofibroblast-like cell responsible for 2 the deposition of extracellular matrix proteins (ECM) such as collagen (2). Activated 3 stellate cells can induce phenotypic changes in cancer cells through the production of 4 growth factors and cytokines that stimulate tumor cell proliferation and induce a pro-5 metastatic phenotype (3). One of the key factors in the cross talk between tumor cells 6 and stellate cells is tumor growth factor beta (TGFβ) (4-6). Malignant hepatocytes 7 secrete high levels of TGFβ, which can contribute to the activation of stellate cells in 8 the nearby stroma. These activated stellate cells are then responsible for the 9 deposition of ECM. Several of the ECM components such as proteoglycans, collagens, 10 laminin, and fibronectin interact with tumor cells and cells in the stroma, which can 11 directly promote cellular transformation and metastasis (7, 8) . The ECM can also act 12 as a reservoir for growth factors and cytokines, which can be rapidly released to 13 support the tumor´s needs. In addition, activated stellate cells contribute to a highly 14 vascularized tumor micro-environment, by secreting pro-angiogenic molecules and by 15 recruiting pro-angiogenic (and pro-tumoral) myeloid and lymphoid derived cell types 16 (9). By constricting the hepatic microvasculature, they also cause hypoxia, which 17 contributes to the angiogenic switch and can induce a more aggressive tumor 18 phenotype (10). It is therefore not surprising that tumor cells actively secrete growth 19 factors (such as TGFβ) to induce activation and migration of stellate cells, which 20 creates a fibrotic environment that further supports and enhances tumor progression 21 (2, 11, 12) . Since activated stellate cells play an essential role in the onset and 22 progression of HCC, blocking their activation has been proposed as a potential therapy 23 for patients with HCC (13). One strategy to block stellate cell activation, is by targeting 24 the unfolded protein response (UPR) . 25 1 The unfolded protein response serves to cope with misfolded or unfolded proteins in 2 the ER in an attempt to restore protein folding, increase ER-biosynthetic machinery 3 and maintain cellular homeostasis (14) . It can exert a cytoprotective effect by re-4 establishing cellular homeostasis, while apoptotic signaling pathways will be activated 5 in case of severe and/or prolonged . The presence of misfolded proteins 6 is sensed via 3 transmembrane proteins in the ER: IRE1α, PERK and ATF6a. Actors 7 of the ER-stress pathways have been described to play a role in the progression of 8 solid tumors, such as breast cancer (16), colon cancer (17) and HCC (18) . Activation 9
of the UPR has also been shown to affect different fibrotic diseases (19), including 10 non-alcoholic fatty liver disease (20) (21) (22) , hepatitis B-induced carcinogenesis (23) and 11 biliary cirrhosis (24) . We have previously shown that inhibiting the IRE1α-branch of the 12 UPR-pathway using 4μ8C, blocks TGFβ-induced activation of fibroblasts and stellate 13 cells in vitro and reduces liver fibrosis in vivo (25) . In the current study, our aim was to 14 define the role of ER-stress in the cross-talk between hepatic stellate cells and tumor 15 cells in liver cancer. We show that pharmacologic inhibition of the IRE1α signaling 16 pathway decreases tumor burden in a chemically induced mouse model for HCC. 17 Using several in vitro co-culturing methods, we identified that tumor cells induce ER-18 stress in hepatic stellate cells. Blocking ER-stress in these hepatic stellate cells 19 prevents their activation and decreases proliferation and migration of tumor cells co-20 cultured with hepatic stellate cells. 21
22

MATERIAL AND METHODS 23
Mouse model 24
Human liver scaffold decellularization and cell culture usage 1 Human healthy livers were obtained under the UCL Royal Free BioBank Ethical 2 Review Committee (NRES Rec Reference: 11/WA/0077) approval. Informed consent 3 was obtained for each donor and confirmed via the NHSBT ODT organ retrieval 4 pathway (31). Liver 3D-scaffolds, were decellularized, sterilized and prepared for cell 5 culture use as preciously described (31). LX2 and HepG2-cells, as either mono-6 cultures or mixed co-culture, were released on top of each scaffold as 2.5*10 5 cells in 7 20µL (32). Nucleofection with 0,1µM siIRE1α (s200432, ThermoFisher), or 0,1 µM siCtrl 17 (4390843, ThermoFisher) was done using Amaxa Nucleofector program S-005 in 18
Ingenio electroporation solution (Mirus Bio LLC, Taastrup, Denmark) . 19 20
Migration and chemotaxis 21
Non-directional migration was assessed using a scratch wound assay on fluorescently 22 labelled LX2-cells and HepG2-cells. Scratch size was measured by analyzing light 23 microscopy images in ImageJ, using the MRI Wound Healing Tool plug-in 24 (http://dev.mri.cnrs.fr/projects/imagej-macros/wiki/Wound_Healing_Tool).
Image 1 analysis was done in ImageJ. 2 Directional migration was assessed using CellDirector-devices (GradienTech, 3 Uppsala, Sweden). HepG2 and LX2-cells were labelled with CellTracker-dye and left 4 to adhere overnight in the CellDirector-devices. Non-adherent cells were washed away 5 with DMEM and cells were starved for 1h prior to commencing experiments. A gradient 6 of 0 to 10% FBS was created with a flow rate of 1.5 µl/minute. Cell movement was 7 recorded using an Axiovision 200M microscope (Zeiss, Stockholm, Sweden) for 4h 8 and tracked using Axiovision software (Zeiss). During the assay cells were kept at 37˚C 9 with 5% CO2. 10
11
Quantitative RT-PCR of mRNA 12 RNA was isolated from tissue or cell culture using the EZNA RNA isolation Kit (VWR, 13 Spånga, Sweden) or using TRIzol reagent and RNeasy Universal Mini Kit (Qiagen, 14 Sollentuna, Sweden) for human liver scaffolds (31). RNA-concentration and purity 15 were evaluated using Nanodrop. Afterwards, 500ng of mRNA was reverse transcribed 16 using iScript cDNA synthesis kit (Bio-rad, Solna, Sweden). Amplifications were done 17 using primers summarized in supplementary table 1. mRNA-expression was 18 normalized to 18S, GAPDH and/or TBP1. Fold change was calculated via the delta-19 delta-CT method, by using the average CT value of 3 technical replicates. 20
The procedure to detect the spliced and unspliced isoforms of XBP1 was done by 21 digesting RT-PCR product with the restriction enzyme Pst-I (ThermoFisher). This 22 cleaves unspliced-XBP1 containing the Pst-I-cleavage site (CTGCA^G), but 23 leaves the spliced isoform intact. The digestion reaction was stopped after 18h by 0,5M 24 EDTA (pH 8.0) and run on a 1,5% agarose gel for 1h at 180V. 25 1
Stainings and immunocytochemistry 2
Tissue samples were fixed in 4% paraformaldehyde for 24h and subsequently 3 embedded in paraffin. Cells and tumor spheroids were fixed for 10 minutes in 4% 4 paraformaldehyde and stored at 4°C. Paraffin embedded tissue samples were cut at 5 5μm and dried overnight. Sections were de-paraffinized and rehydrated prior to 6 staining. Collagen was stained using the picrosirius red staining with an incubation time 7 of 30 minutes, followed by 10 minutes washing in distilled water. Haematoxilin-eosin 8 (H&E) staining was done according to standard practice. Images were acquired using 9 a Nikon eclipse 90i microscope equipped with a DS-Qi1Mc camera and Nikon plan 10 Apo objectives. NIS-Elements AR 3.2 software was used to save and export images. 11
Quantification of collagen deposition was performed blindly with ImageJ software by 12 conversion to binary images after color de-convolution to separate Sirius Red staining, 13 as previously described (33). 14
15
Paraformaldehyde fixed cells and spheroids were washed with tris-buffer saline (TBS) 16 and blocked for 30 minutes using 1% bovine serum albumin in TBS + 0,1% Tween. 17
For liver tissue, antigen retrieval was done at 95°C in sodium citrate buffer and 18 endogenous mouse IgG was blocked using a rodent blocking buffer (ab127055, 19 abcam) following manufacturer´s guidelines. Blocking was followed by an overnight 20 incubation at 4°C with antibodies against α-smooth muscle actin (αSMA) (clone 1A4, 21 Sigma), Bip (ab21685, abcam) or p-IRE1α (PAB12435, Abnova). A 40-minute 22 incubation was used for the secondary antibody (Rabbit anti-mouse Alexa Fluor-488 23 or donkey anti-rabbit Alexa Fluor-633) and cell nuclei were stained with Hoechst for 8 24 minutes. Images were taken using an inverted confocal microscope (LSM 700, Zeiss) 25 using Plan-Apochromat 20× objectives and the Zen 2009 software (Zeiss). The 1 different channels of immunofluorescent images were merged using ImageJ software. 2
Quantifications were done blindly with ImageJ software by conversion to binary images 3 for each channel and automated detection of staining on thresholded images using a 4 macro. 5 6 For histological and immunohistochemical analysis of the human liver scaffolds, 4μm 7 slides were cut from paraffin embedded blocks. The sections were de-paraffinized and 8 rehydrated prior to staining. To retrieve the antigens, slides were microwaved at high 9 power for 5 minutes in pre-heated 10 mM sodium citrate buffer, and subsequently left 10 to cool down to room temperature. Following this, a single wash was performed in 100 11 mM Glycine in PBS, after which the slides were blocked for 2h in TNB Blocking 12 Reagent (Ancillary Products, FP1020). Slides were then incubated for 2h in the 13 following antibodies; Ki67 (1:100; eBioscience™, SolA15), and EPCAM (1:100; 14 Abcam, ab71916). A 1h incubation was used for the secondary antibody (goat anti-rat 15
Alexa Fluor 555 and Rabbit anti-mouse Alexa Fluor 488). Sections were mounted with 16
Fluoromount-G TM , with DAPI (Invitrogen, 00-4959-52). Images were taken with using 17 an inverted confocal microscope (LSM 780, Zeiss) using Plan-Apochromat 10× 18 objectives and the Zen 2009 software (Zeiss). 19 20
Enzyme-Linked immune Sorbent Assay (ELISA) 21
Medium samples from cells and from the engrafted scaffolds were used to measure 22
TGFβ using ELISA (88-8350-22, ThermoFisher), following manufacturer´s guidelines. 23
The average from 2 technical replicates were used for calculations. 24
25
SDS-PAGE and western blot 1
Protein lysates in lysis buffer were mixed with 2x laemmli buffer and heated to 95˚C 2 for 5 minutes before being loaded onto a 10% polyacrylamide gel. After separation, 3 the proteins were transferred to an Immobilon-Fl membrane (Millipore). The membrane 4 was blocked using the Odyssey blocking buffer (Licor) diluted 1:4 in PBS, and then 5 incubated with primary and secondary antibodies. After primary and secondary 6 antibody incubation the membrane was washed 3x15 minutes in PBS-T (Phosphate 7 buffered saline (Gibco), 0.1% Tween-20). Primary antibodies used were Bip (ab21685, 8 abcam), p-IRE1α (PAB12435, Abnova) or vinculin (14-9777-82, ThermoFisher) all 9 added in blocking buffer with 0.1% Tween-20. Secondary antibodies used were: goat-10 anti-mouse alexa 680 (Invitrogen) and goat-anti-rabbit IRDye 800 (Rockland) 1:20 000 11 diluted in blocking buffer with 0.1% Tween-20 and 0.01% SDS. All incubations were 12 carried out at room temperature for 1h or overnight at 4˚C. The membranes were 13 scanned using an Odyssey scanner (LI-COR Biotechnology) and band intensities 14 Data are presented as mean ± s.e.m. Statistical significance was determined using an 6 unpaired, two-tailed Student's T-test or one-way analysis of variance (ANOVA) 7 followed by Tukey´s multiple comparison test. Survival curves were generated with the 8 Kaplan-Meier method and statistical comparisons were made using the log-rank 9 method. P-values <0.05 were considered statistically significant. In vitro experiments 10 were done in at least 3 biological replicates, which we define as parallel measurements 11 of biologically distinct samples taken from independent experiments. Technical 12 replicates we define as loading the same sample multiple times on the final assay. The 13
in vivo experiments were done on at least 5 independent animals. Outliers were kept 14 in the analyses, unless they were suspected to occur due to technical errors, in which 15 case the experiment was repeated. Red staining ( Figure 1A and 1C) and immunohistochemical staining with αSMA-2 antibodies ( Figure 1A and 1D) on liver sections. Mice with HCC had a significant 3 increase in the percentage of collagen ( Figure 1C ) and αSMA-staining ( Figure 1D) , 4 compared to healthy mice. Treatment with 4µ8C restored collagen ( Figure 1C) and 5 αSMA-levels ( Figure 1D and Figure 1E ) to a similar level as healthy livers. mRNA 6 expression levels of PCNA were determined on tumor nodules and surrounding non-7 tumor stromal tissue ( Figure 1E ). As expected, proliferation of cells was increased 8 within the tumor itself, compared to the levels seen in healthy liver tissue and stromal 9 tissue. Treatment with 4μ8C significantly decreased the levels of PCNA mRNA 10 expression within the tumor, suggesting a decrease in tumor cell proliferation. A 11 proteomics array using the Olink Mouse Exploratory assay revealed that DEN-induced 12 murine tumors had a significantly increased protein expression of 20 oncogenic 13 proteins compared to healthy controls ( Figure 1F and table 1). In the 4μ8C-treated 14 group, only 11 oncogenic proteins were increased compared to healthy controls 15 ( Figure 1F and table 1). Treatment with 4μ8C also significantly reduced the expression 16 of two HCC promotors, Prdx5 and DDah1 ( Figure 1F figure 1E) in 3 untreated mice with HCC, revealed that expression of ER-stress markers was mainly 4 localized within activated stellate cells in the liver. 5
A gene-set enrichment assay on microarray data from HCC-patients with fibrotic 6 septae and without fibrotic septae showed an increase of genes involved in the UPR 7 in the fibrotic HCC samples compared to non-fibrous HCC (supplementary figure 2A) . 8
Several actors of the IRE1α-branch of the UPR are amongst the genes that contribute 9 to the core-enrichment of this analysis (table 2) . Immunohistochemical staining of liver 10 biopsies from HCC-patients further confirmed presence of IRE1α-mediated ER-stress 11 markers BiP, PPP2R5B, SHC1 and WIPI1 localized in the fibrotic scar tissue and near 12 hepatic blood vessels (Supplementary figure 2B ). In addition, increased expression of 13 these markers was significantly correlated with poor survival in patients with liver 14 cancer (Supplementary figure 2C) . 15 16
Tumor cells secrete factors that induce ER-stress in hepatic stellate cells 17
Hepatic stellate cell-lines (LX2) and HCC-cell lines (HepG2 and Huh7) were grown in 18 different compartments using a transwell assay. This confirmed that tumor cells 19 secrete factors that increase mRNA-expression of CHOP (Figure 2A of ER-stress. This also led to their activation, as measured by mRNA-expression of 23 αSMA ( Figure 2F ) and collagen ( Figure 2G ) in LX2-cells grown with HepG2 or Huh7 24 cells in a transwell assay. The mRNA-expression of αSMA and collagen was restored 1 to baseline levels when 4µ8C was added to the transwell co-cultures. 2
De-cellularised human liver 3D-scaffolds were engrafted with hepatic stellate cells 3 (LX2) and tumor cells (HepG2). Sirius red staining and H&E staining confirmed that 4 that LX2-cells and HepG2-cells successfully engrafted the collagen-rich matrix of the 5 decellularized human liver scaffolds ( Figure 3A ). Engrafting both LX2-stellate cells and 6
HepG2-cancer cells led to a significant increase of mRNA-expression of collagen, BiP 7 and spliced XBP1 ( Figure 3B ) compared to scaffolds that were only engrafted with 8 LX2-cells. Adding 4μ8C significantly decreased mRNA expression of collagen and BiP-9 mRNA-expression in the LX2 and HepG2 co-cultured scaffolds ( Figure 3B ). 10
Tumor cells are important sources of TGFb, which is a known activator of stellate cells. 11
Surprisingly, measuring TGFb in mono-cultures lead to undetectable levels of TGFb in 12
Huh7-cells and low-levels in HepG2-cells (Supplementary figure 3A ). These levels 13 increased when LX2-cells were added to the co-cultures (Supplementary figure 3A) . 14
Engrafting both LX2-stellate cells and HepG2-cancer cells in the human liver scaffolds, 15
slightly increased TGFb-levels in the medium compared to scaffolds engrafted by only 16 one cell type, but overall no significant differences were seen (Supplementary figure 17 3B). It is important to note that the baseline TGFb-levels were markedly higher in the 18 mono-cultured scaffolds, compared to the levels measured in cells grown in a standard 19 2D in vitro set-up (Supplementary figure 3A) . Blocking TGFb-receptor signaling with 20 SB-431541 significantly reduced mRNA-expression of ER-stress markers CHOP 21 Adding a TGFb-receptor-inhibitor to stellate cell -tumor cell co-cultures also reduced 24 stellate cell activation, as measured by mRNA-expression of αSMA (Supplementary 1 figure 3G ) and collagen (Supplementary figure 3H ). This indicates that TGFb-secretion 2 by tumor cells could be responsible for activating stellate cells and for inducing the 3
UPR. 4 5
Pharmacological inhibition of IRE1α decreases tumor cell proliferation in stellate 6
cell -tumor cell co-cultures 7
In transwell co-culturing assays, we found that co-culturing HepG2 or Huh7-tumor cells 8 with LX2-stellate cells significantly increased PCNA-mRNA-expression in HepG2 and 9
Huh7-tumor cell lines ( Figure 4A ). Adding 4μ8C significantly decreased mRNA-10 expression of PCNA in Huh7-cells grown in a transwell co-culture with LX2-cells, while 11 not affecting PCNA-expression in tumor cell mono-cultures ( Figure 4A ). PCNA-levels 12
in HepG2-LX2 transwell co-cultures were slightly decreased, but this was not 13 significant. Proliferation was measured 24h after exposure to 4μ8C in tumor cells 14 (HepG2 and Huh7) grown as mono-cultures and in co-culture with LX2-stellate cells. 15
While 4μ8C induced a significant increase in proliferation of HepG2-monocultures, no 16 difference was seen in LX2-monocultures and a significant decrease was seen in the 17
HepG2-LX2 co-cultures ( Figure 4B ). In the Huh7 tumor cell line, 4μ8C significantly 18 decreased cell number compared to untreated controls and a similar reduction was 19 seen in the Huh7-LX2 co-cultures ( Figure 4C ). Immunohistochemical staining with 20 antibodies against Epcam and Ki67 show that the effect on proliferation is mainly 21 localized in the tumor cell population of these co-cultures ( Figure 4D ). 22
3D-spheroids were generated using tumor cells alone (HepG2 or Huh7) or in 23 combination with LX2-cells. While the HepG2-spheroids experienced a lower 24 proliferation rate when co-cultured with LX2 stellate cells ( Figure 4E ), there was no 1 difference in proliferation between spheroid-monocultures and spheroid-co-cultures in 2 the Huh7-cells ( Figure 4F ). Treatment with 4μ8C significantly decreased proliferation 3 of the tumor spheroids consisting of tumor cells (Huh7 or HepG2) and stellate cells 4 (LX2), while tumor spheroid monocultures were not affected by 4μ8C. Similarly, PCNA-5 mRNA-expression significantly increased in human liver scaffolds engrafted with 6
HepG2 and LX2-cells, compared to those engrafted with only tumor cells ( Figure 5A ). 7
Treatment with 4μ8C significantly decreased PCNA-mRNA-expression in the 8 LX2+HepG2 liver scaffolds, whilst not affecting those engrafted with only tumor cells. 9
This further confirms our hypothesis that 4μ8C affects tumor cell proliferation indirectly, 10 namely by blocking the activation of stellate cells and thus impairing the interaction 11 between tumor and stroma. 12
We measured the mRNA-expression of hepatocyte-nuclear-factor-4-alpha (Hnf4-α), 13 which is a liver function marker that is correlated to a favorable outcome for HCC-14 patients (42). While co-engraftment of LX2 and HepG2-cells in the liver scaffolds only 15 lead to a marginal increase of Hnf4-α, treatment with 4μ8C significantly increased 16
Hnf4-α-mRNA-expression, thus suggesting an overall improvement of liver function 17 and possibly improved prognosis ( Figure 5B ). Immunohistochemical staining of Epcam 18 and ki67, showed that the HCC-cells have successfully engrafted the entire surface of 19 the scaffolds and that 4μ8C decreases proliferation ( Figure 5C ). 20 21
Pharmacological inhibition of IRE1α decreases tumor cell migration in stellate 22
cell -tumor cell co-cultures 23
Co-culturing HepG2 and Huh7-tumor cells with LX2-cells in the transwell assays 24 significantly increased mRNA-expression of the pro-metastatic marker MMP9 in 25
HepG2-cells ( Figure 6A ) and MMP1 in HepG2 and Huh7-cells ( Figure 6B ). Adding 1 4μ8C significantly decreased the mRNA-expression of MMP1 in HepG2+LX2 and 2
Huh7+LX2 transwell co-cultures, while a non-significant decrease of MMP9 mRNA-3 expression was seen in Huh7+LX2 transwell co-cultures. To assess whether this 4 reduction in mRNA-expression of pro-metastatic markers has a functional effect on cell 5 migration, a scratch wound assay was performed on confluent monolayers of mono-6 cultures (HepG2 or LX2) or tumor cell (HepG2) stellate cells) ( Figure 6D ). Tumor-stellate cell co-cultures were the most efficient to 10 close the scratch wound ( Figure 6E ). This was significantly inhibited when co-cultures 11
were treated with 4μ8C. We also observed a direct effect of 4μ8C on LX2 and HepG2-12 migration, since treatment with 4μ8C lead to a significant reduction in wound closure 13 after 24h, compared to untreated controls. It is important to note that traditional scratch 14 wound assays cannot distinguish between proliferation and migration (43). To HepG2-cells. Overall, these data suggest that stellate cells increase proliferation and 5 pro-metastatic potential of tumor cells and blocking the IRE1α-RNase activity 6 decreases tumor cell proliferation and migration. 7 8
Silencing of IRE1α in stellate cells decreases tumor cell proliferation and 9 migration in co-cultures 10
To investigate whether the effect of blocking IRE1α is due to a direct effect on the 11 tumor cells or because of an indirect effect via stellate cells, we transfected the stellate-12 line LX2 with an IRE1α-siRNA prior to co-culturing them in a transwell assay with 13
HepG2-cells. Transfection efficiency was determined via qPCR and showed a 50% 14 reduction in the IRE1α-mRNA-expression ( Figure 7A ) compared to non-transfected 15 (Ctrl) or mock-transfected (Scr) controls. In the transwell co-culturing assay, we found 16 that silencing IRE1α in the LX2-cells significantly decreased PCNA-mRNA-expression 17 in HepG2-cells ( Figure 7B ). Silencing IRE1α in the LX2-cells lead to a significant 18 reduction of proliferation in LX2-HepG2 co-cultures ( Figure 7C ) and LX2-HepG2 19 spheroids ( Figure 7D ). Immunocytochemical staining with αSMA-antibodies ( Figure  20 7E), confirmed a significant reduction of αSMA after si-IRE1α-transfection of LX2-21 stellate cells in HepG2-LX2 spheroid co-cultures ( Figure 7F ). A scratch wound assay 22 on HepG2-LX2 co-cultures verified that silencing of IRE1α in LX2-cells significantly 23 reduced wound closure compared to non-transfected and mock-transfected stellate 24 cells ( Figure 7G -H) . Overall, these data confirm that blocking the IRE1α-pathway in 25 hepatic stellate cells decreases proliferation and pro-metastatic potential of tumor 1
There is increasing evidence that ER-stress and activation of the UPR play an 5 essential role during hepatic inflammation and chronic liver disease. We have 6 previously shown that inhibition of IRE1α prevents stellate cell activation and reduces 7 liver cirrhosis in vivo (25). In this report, we further define a role of ER-stress and the 8 UPR in the interaction between tumor cells and hepatic stellate cells. We also show 9 that IRE1α could form a valuable therapeutic target to slow down the progression of 10 hepatocellular carcinoma. 11 12 Activated stellate cells play an important role in promoting tumorigenesis and tumors 13 are known to secrete cytokines such as TGFβ, which induce myofibroblast activation 14 and creates an environment that sustains tumor growth (46). Since over 80% of HCC 15 arises in a setting of chronic inflammation associated with liver fibrosis, targeting the 16 fibrotic tumor micro-environment is often proposed as a valuable therapeutic strategy 17 for HCC-patients (2). We and others have shown that ER-stress plays an important 18 role in stellate cell activation and contributes to the progression of liver fibrosis (25, 47-19 49) . The mechanisms by which the UPR promotes stellate cell activation have been 20 attributed to regulating the expression of c-MYB (25), increasing the expression of 21 SMAD-proteins (47) and/or by triggering autophagy (49) . 22
23
In our study, we show that ER-stress plays an important role in stellate cell -tumor 24 cell interactions and that pharmacological inhibition of IRE1α-endoribonuclease activity 25 slows down the progression of HCC in vivo. We demonstrate that tumor cells induce 1 ER-stress in hepatic stellate cells, thereby contributing to their activation and creating 2 an environment that is supportive for tumor growth and metastasis. Activated stellate 3 cells are known to enhance migration and proliferation of tumor cells in vitro (8) and in 4 vivo (50), possibly by producing extracellular matrix proteins and by producing growth 5 factors. Extracellular matrix proteins such as collagen can act as a scaffold for tumor 6 cell migration (51), alter the expression of MMP´s (8) and induce epithelial-7 mesenchymal transition (52). Activated stellate cells are also an important source of 8 hepatocyte growth factor, which promotes proliferation, cell invasion and epithelial-9 mesenchymal transition via the c-MET signaling pathway (53). Interestingly, blocking 10 ER-stress in the stellate cell population reduced tumor-induced activation towards 11 myofibroblasts, which then decreases proliferation and migration of tumor-cells in co-12
cultures. This suggests that targeting the microenvironment using an ER-stress 13 inhibitor could be a promising strategy for patients with HCC. 14
15
The UPR has been described as an essential hallmark of HCC (54), although its role 16 within tumorigenesis remains controversial (18). While a mild to moderate level to ER-17 stress leads to activation of the UPR and enables cancer cells to survive and adapt to 18 adverse environmental conditions, the occurrence of severe or sustained ER-stress 19 leads to apoptosis. Both ER-stress inhibitors as ER-stress inducers have therefore 20 been shown to act as potential anti-cancer therapies (55). A recent study by Wu et al, 21 demonstrated that IRE1α promotes progression of HCC and that hepatocyte specific 22 ablation of IRE1α results in a decreased tumorigenesis (56) . In contrast to their study, 23
we found a greater upregulation of actors of the IRE1α-branch within the stroma than 24 in the tumor itself and identified that expression of ER-stress markers was mainly 25 localized within the stellate cell population. An important difference between both 1 studies is the mouse model that is used. While Wu et al used a single injection of DEN, 2 we performed weekly injections, causing tumors to occur in a background of fibrosis, 3 similar to what is seen in patients (26). Our in vitro studies with mono-cultures confirm 4 that 4μ8C also has a direct effect on proliferation and migration of HCC cells -similar 5 to the findings of Wu et al -and the response seems to depend on the tumor cell line. 6
Adding 4μ8C to HepG2-cells significantly increased proliferation, while a significant 7 decrease was seen in the Huh7-cells. This difference in response could be due 8
IRE1α´s function as a key cell fate regulator. On the one hand it can induce 9 mechanisms that restore protein homeostasis and promote cytoprotection, while on 10 the other hand IRE1α also activates apoptotic signaling pathways. How and when 11
IRE1α exerts its cytoprotective or its pro-apoptotic function remains largely unknown. 12
The duration and severity of ER-stress seems to be a major contributor to the switch 13 HepG2-cells (59). Similar to our findings, they discovered that inhibiting IRE1α 20 enhances cell proliferation, while over-expression of IRE1α increases the expression 21 of polo-like kinase, which leads to apoptosis. Interestingly, polo-like kinases have 22 divergent roles on HCC-cell growth depending on which cell line is used, which could 23 explain the different response to 4μ8C in Huh7 and HepG2-cells (60). Studies on 24 glioma cells show that IRE1α regulates invasion through MMP´s (61). In line with these 25 results, we also detected a reduction of MMP1-mRNA expression after 4μ8C-treatment 1 and observed a direct effect on wound closure in HepG2-cells. These results indicate 2 that ER-stress could play a direct role in regulating tumor cell invasion, in addition to 3 its indirect effect via stellate cells. 4 5
In conclusion, the aim of this study was to define the role of ER-stress in the cross-talk 6 between hepatic stellate cells and tumor cells in liver cancer. We show that 7 pharmacologic inhibition of the IRE1α-signaling pathway decreases tumor burden in a 8 DEN-induced mouse model for HCC. Using several in vitro 2D and 3D co-culturing 9 methods, we identified that tumor cells induce ER-stress in hepatic stellate cells and 10 that this contributes to their activation. Blocking ER-stress in these hepatic stellate cells 11 prevents their activation, which then decreases proliferation and migration of tumor 12 cells. 13 14 15
ACKNOWLEDGEMENTS 16
This research was funded through grants obtained from the Swedish Cancer 17 Foundation (Cancerfonden, CAN2017/518 and CAN2013/1273), The Swedish 18 children's cancer foundation (Barncancerfonden), the Swedish society for medical 19 research (SSMF, S17-0092), the O.E. och Edla Johanssons stiftelse. These funding 20 sources were not involved in the study design; collection, analysis and interpretation 21 of data; writing of the report; and in the decision to submit the article for publication. 22
We would like to thank visiting students Kim Vanhollebeke and Justine Dobbelaere for 23 their technical assistance; GradienTech for providing us with their CellDirector assays 24 and Paul O´Callaghan for his valuable input on our project. 25 
